Showing results (191-200 of 208) with videos related to
Sort By:
Pageof 21
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline UpdateRahul Seth, Sanjiv S Agarwala, Hans Messersmith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2020
Systemic Therapy for Melanoma: ASCO GuidelineRahul Seth, Hans Messersmith, Varinder Kaur, et al.The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.Cancer Research Communications|February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic MelanomaEva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.Pageof 21